MaxCyte, Inc. Financing Cash Flow
MaxCyte, Inc. (MXCT) reported Financing Cash Flow of -$1.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- MaxCyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.42M, a 1022.08% decline year-over-year.
- MaxCyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.00K, a 98.69% decline year-over-year.
- MaxCyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $105.00K, a 74.51% decline year-over-year.
- MaxCyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $14.00K, a 93.86% decline year-over-year.
- MaxCyte, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $656.00K, a 68.09% decline from fiscal 2024.
- MaxCyte, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $2.06M, a 4.06% decline from fiscal 2023.
- MaxCyte, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $2.14M, a 25.80% decline from fiscal 2022.
- MaxCyte, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $2.89M, a 98.77% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.42M 10-Q · filed 2026-08-13 | -$1.31M derived: sum of 3 quarters · filed 2026-08-13 | -$1.30M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $5.00K 10-Q · filed 2026-05-13 | $110.00K derived: sum of 2 quarters · filed 2026-05-13 | $124.00K derived: sum of 3 quarters · filed 2026-05-13 | $278.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $119.00K derived: sum of 2 quarters · filed 2026-03-25 | $273.00K derived: sum of 3 quarters · filed 2026-08-13 | $656.00K 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $168.00K derived: sum of 2 quarters · filed 2026-08-13 | $551.00K 10-Q · filed 2025-11-13 | $963.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $537.00K 10-Q · filed 2026-08-13 | $949.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.18M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $383.00K 10-Q · filed 2026-05-13 | $795.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.02M derived: sum of 3 quarters · filed 2026-05-13 | $1.74M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $640.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.35M derived: sum of 3 quarters · filed 2026-03-25 | $2.06M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $941.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.64M 10-Q · filed 2025-11-13 | $2.14M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $713.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.42M 10-Q · filed 2025-08-06 | $1.91M derived: sum of 3 quarters · filed 2025-08-06 | $1.95M derived: sum of 4 quarters · filed 2025-08-06 | |||
| 2024-03-31 | $703.00K 10-Q · filed 2025-05-08 | $1.20M derived: sum of 2 quarters · filed 2025-05-08 | $1.23M derived: sum of 3 quarters · filed 2025-05-08 | $1.39M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $530.00K derived: sum of 2 quarters · filed 2025-03-11 | $687.00K derived: sum of 3 quarters · filed 2025-03-11 | $2.14M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $194.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.65M 10-Q · filed 2024-11-06 | $2.88M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.61M 10-Q · filed 2024-08-06 | $1.61M 10-Q · filed 2023-08-09 | $2.84M derived: sum of 3 quarters · filed 2024-08-06 | $3.28M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $1.46M 10-Q · filed 2024-05-07 | $1.46M 10-Q · filed 2023-05-10 | $2.68M derived: sum of 2 quarters · filed 2024-05-07 | $3.13M derived: sum of 3 quarters · filed 2024-05-07 | $3.45M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.67M derived: sum of 2 quarters · filed 2024-03-12 | $2.00M derived: sum of 3 quarters · filed 2024-03-12 | $2.89M 10-K · filed 2024-03-12 | $2.89M 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $444.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $769.90K derived: sum of 2 quarters · filed 2023-11-08 | $1.66M 10-Q · filed 2023-11-08 | $2.87M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $325.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.22M 10-Q · filed 2023-08-09 | $2.43M derived: sum of 3 quarters · filed 2023-08-09 | $187.01M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $892.60K 10-Q · filed 2023-05-10 | $2.10M derived: sum of 2 quarters · filed 2023-05-10 | $186.69M derived: sum of 3 quarters · filed 2023-05-10 | $186.71M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $185.79M derived: sum of 2 quarters · filed 2023-03-15 | $185.82M derived: sum of 3 quarters · filed 2023-03-15 | $234.72M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $184.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $184.61M derived: sum of 2 quarters · filed 2022-11-09 | $233.51M 10-Q · filed 2022-11-09 | $233.60M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $27.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $48.93M 10-Q · filed 2022-08-10 | $49.02M derived: sum of 3 quarters · filed 2022-08-10 | $49.28M derived: sum of 4 quarters · filed 2022-08-10 | |||
| 2021-03-31 | $48.90M 10-Q · filed 2022-05-09 | $48.99M derived: sum of 2 quarters · filed 2022-05-09 | $49.25M derived: sum of 3 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $90.90K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $353.00K derived: sum of 2 quarters · filed 2022-03-22 | $28.90M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $262.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $28.81M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $28.55M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $12.31M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |